Quantitative diffusion-weighted MRI response assessment in rhabdomyosarcoma: an international retrospective study on behalf of the European paediatric Soft tissue sarcoma Study Group Imaging Committee
-
Published:2023-09-08
Issue:12
Volume:53
Page:2539-2551
-
ISSN:1432-1998
-
Container-title:Pediatric Radiology
-
language:en
-
Short-container-title:Pediatr Radiol
Author:
van Ewijk RoelofORCID, Chatziantoniou CyranoORCID, Adams Madeleine, Bertolini Patrizia, Bisogno GianniORCID, Bouhamama AmineORCID, Caro-Dominguez PabloORCID, Charon ValerieORCID, Coma AnaORCID, Dandis RanaORCID, Devalck ChristineORCID, De Donno GiuliaORCID, Ferrari AndreaORCID, Fiocco MartaORCID, Gallego SoledadORCID, Giraudo ChiaraORCID, Glosli HeidiORCID, ter Horst Simone A. J.ORCID, Jenney Meriel, Klein Willemijn M.ORCID, Leemans AlexanderORCID, Leseur Julie, Mandeville Henry C.ORCID, McHugh KieranORCID, Merks Johannes H. M.ORCID, Minard-Colin VeroniqueORCID, Moalla SalmaORCID, Morosi CarloORCID, Orbach DanielORCID, Ording Muller Lil-SofieORCID, Pace ErikaORCID, Di Paolo Pier LuigiORCID, Perruccio Katia, Quaglietta LuciaORCID, Renard Marleen, van Rijn Rick R.ORCID, Ruggiero AntonioORCID, Sirvent Sara I., De Luca AlbertoORCID, Schoot Reineke A.ORCID
Abstract
Abstract
Objective
To investigate the feasibility of diffusion-weighted magnetic resonance imaging (DW-MRI) as a predictive imaging marker after neoadjuvant chemotherapy in patients with rhabdomyosarcoma.
Material and methods
We performed a multicenter retrospective study including pediatric, adolescent and young adult patients with rhabdomyosarcoma, Intergroup Rhabdomyosarcoma Study group III/IV, treated according to the European paediatric Soft tissue sarcoma Study Group (EpSSG) RMS2005 or MTS2008 studies. DW-MRI was performed according to institutional protocols. We performed two-dimensional single-slice tumor delineation. Areas of necrosis or hemorrhage were delineated to be excluded in the primary analysis. Mean, median and 5th and 95th apparent diffusion coefficient (ADC) were extracted.
Results
Of 134 included patients, 82 had measurable tumor at diagnosis and response and DW-MRI scans of adequate quality and were included in the analysis. Technical heterogeneity in scan acquisition protocols and scanners was observed. Mean ADC at diagnosis was 1.1 (95% confidence interval [CI]: 1.1–1.2) (all ADC expressed in * 10−3 mm2/s), versus 1.6 (1.5–1.6) at response assessment. The 5th percentile ADC was 0.8 (0.7–0.9) at diagnosis and 1.1 (1.0–1.2) at response. Absolute change in mean ADC after neoadjuvant chemotherapy was 0.4 (0.3–0.5). Exploratory analyses for association between ADC and clinical parameters showed a significant difference in mean ADC at diagnosis for alveolar versus embryonal histology. Landmark analysis at nine weeks after the date of diagnosis showed no significant association (hazard ratio 1.3 [0.6–3.2]) between the mean ADC change and event-free survival.
Conclusion
A significant change in the 5th percentile and the mean ADC after chemotherapy was observed. Strong heterogeneity was identified in DW-MRI acquisition protocols between centers and in individual patients.
Graphical Abstract
Funder
Stichting Kinderen Kankervrij
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,Pediatrics, Perinatology and Child Health
Reference32 articles.
1. van Ewijk R, Vaarwerk B, Breunis WB, Schoot RA, Ter Horst SAJ, van Rijn RR, van der Lee JH, Merks JHM (2021) The value of early tumor size response to chemotherapy in pediatric rhabdomyosarcoma. Cancers (Basel) 13(3):510 2. Bisogno G, Jenney M, Bergeron C, GallegoMelcon S, Ferrari A, Oberlin O, Carli M, Stevens M, Kelsey A, De Paoli A, Gaze MN, Martelli H, Devalck C, Merks JH, Ben-Arush M, Glosli H, Chisholm J, Orbach D, Minard-Colin V, De Salvo GL, European paediatric Soft tissue sarcoma Study G (2018) Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol 19:1061–1071 3. Bisogno G, De Salvo GL, Bergeron C, GallegoMelcon S, Merks JH, Kelsey A, Martelli H, Minard-Colin V, Orbach D, Glosli H, Chisholm J, Casanova M, Zanetti I, Devalck C, Ben-Arush M, Mudry P, Ferman S, Jenney M, Ferrari A, European paediatric Soft tissue sarcoma Study G (2019) Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20:1566–1575 4. Taouli B, Beer AJ, Chenevert T, Collins D, Lehman C, Matos C, Padhani AR, Rosenkrantz AB, Shukla-Dave A, Sigmund E, Tanenbaum L, Thoeny H, Thomassin-Naggara I, Barbieri S, Corcuera-Solano I, Orton M, Partridge SC, Koh DM (2016) Diffusion-weighted imaging outside the brain: Consensus statement from an ISMRM-sponsored workshop. J Magn Reson Imaging 44:521–540 5. Humphries PD, Sebire NJ, Siegel MJ, Olsen OE (2007) Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology 245:848–854
|
|